Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2044-5385
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients ; volume:10 ; number:11 ; day:9 ; month:11 ; year:2020 ; pages:1-8 ; date:11.2020
Blood cancer journal ; 10, Heft 11 (9.11.2020), 1-8, 11.2020
- Urheber
-
Krull, Jordan E.
Wenzl, Kerstin
Hartert, Keenan T.
Manske, Michelle K.
Sarangi, Vivekananda
Maurer, Matthew J.
Larson, Melissa C.
Nowakowski, Grzegorz S.
Ansell, Stephen M.
McPhail, Ellen
Habermann, Thomas M.
Link, Brian K.
King, Rebecca L.
Cerhan, James R.
Novak, Anne J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-020-00382-3
- URN
-
urn:nbn:de:101:1-2020122020445803618049
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Krull, Jordan E.
- Wenzl, Kerstin
- Hartert, Keenan T.
- Manske, Michelle K.
- Sarangi, Vivekananda
- Maurer, Matthew J.
- Larson, Melissa C.
- Nowakowski, Grzegorz S.
- Ansell, Stephen M.
- McPhail, Ellen
- Habermann, Thomas M.
- Link, Brian K.
- King, Rebecca L.
- Cerhan, James R.
- Novak, Anne J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)
Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2
GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner
Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement
Phenotyping of cancer-associated somatic mutations in the BCL2 transmembrane domain
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements
High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma
50% versus 70%: is there a difference between these BCL2 cut-offs in immunohistochemistry for diffuse large B-cell lymphomas (DLBCL)?
Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level
c-MYC Triggers Lipid Remodelling During Early Somatic Cell Reprogramming to Pluripotency
Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)
Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2
GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner
Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement
Phenotyping of cancer-associated somatic mutations in the BCL2 transmembrane domain
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements
High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma
50% versus 70%: is there a difference between these BCL2 cut-offs in immunohistochemistry for diffuse large B-cell lymphomas (DLBCL)?
Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level
c-MYC Triggers Lipid Remodelling During Early Somatic Cell Reprogramming to Pluripotency
Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)
Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2
GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner
Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement
Phenotyping of cancer-associated somatic mutations in the BCL2 transmembrane domain
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements
High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma
50% versus 70%: is there a difference between these BCL2 cut-offs in immunohistochemistry for diffuse large B-cell lymphomas (DLBCL)?
Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level